|
⚲
|
| Commodore Capital LP
✚
|
|
|---|---|
| CRD # | 304370 |
| SEC # | 801-117168 |
| CIK # | 0001831942 |
| AUM | $1.4 BB (2024-03-22) |
| Employees | 12 (50% Investors, 0% Brokers) |
| Phone | 212-256-8600 |
| Address | 444 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($MM) |
|---|
| CIK | Period |
|---|---|
| 0001831942 | |
| / | |
| Sector | Form 13F Holdings | Cap ($MM) | Value ($MM) |
|---|---|---|---|
| Merus NV | 941.6 | 189.3 | |
| Nuvalent Inc | 644.5 | 112.9 | |
| Xenon Pharmaceuticals Inc | 1,599.0 | 107.4 | |
| Vaxcyte Inc | 1,215.3 | 98.5 | |
| Imara Inc | 92.9 | ||
| Vera Therapeutics Inc | 360.7 | 89.5 | |
| UNUM Therapeutics Inc | 567.1 | 82.1 | |
| Capnia Inc | 21.0 | 58.1 | |
| Celldex Therapeutics Inc | 1,341.4 | 52.7 | |
| MIND Medicine Mindmed Inc | 287.3 | 51.5 | |
| Rhythm Pharmaceuticals Inc | 218.7 | 50.3 | |
| Arvinas Inc | 2,269.1 | 50.2 | |
| Aeglea Biotherapeutics Inc | 46.7 | ||
| Pharvaris NV | 663.4 | 34.0 | |
| Alkermes PLC | 4,988.1 | 33.1 | |
| Signal Genetics Inc | 293.2 | 32.9 | |
| Zeta Acquisition Corp III | 1,163.5 | 32.8 | |
| Nkarta Inc | 587.6 | 24.5 | |
| Celcuity Inc | 128.6 | 24.0 | |
| Third Harmonic Bio Inc | 20.1 | ||
| Health Sciences Acquisitions Corp | 331.3 | 19.8 | |
| Abivax Sa | 17.0 | ||
| Syndax Pharmaceuticals Inc | 1,042.0 | 16.9 | |
| C4 Therapeutics Inc | 348.9 | 15.8 | |
| Oric Pharmaceuticals Inc | 191.9 | 14.1 | |
| Apogee Therapeutics Inc | 11.4 | ||
| Cabaletta Bio Inc | 30.1 | 8.2 | |
| Aquinox Pharmaceuticals Inc | 7.3 | ||
| Prev | Page 1 | Next | |||
| Type | Form D Funds | Date | Sold ($MM) | AUM ($MM) |
|---|---|---|---|---|
| HF | Commodore Capital Master LP | [2019-07-15] | 648.4 | 1,356.4 |
| AUM Breakdown | Accounts | AUM ($MM) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 1,356.4 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 1,356.4 |
| By Discretionary | ||
| Discretionary | 3 | 1,356.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 1,356.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 245.1 | |
| United States Persons | 1,111.3 | |
| Total | 3 | 1,356.4 |
| Form D Directors | # Filings | # Firms | 2011 - 2024 |
|---|---|---|---|
| Egen Atkinson | 2 | ||
| Michael Kramarz | 2 | ||
| Commodore Capital LP | 2 | ||
| Commodore Capital Domestic GP LP | 1 |
| EDGAR Form | CIK | 2011 - 2024 |
|---|---|---|
| 13F-HR | [0001831942] | |
| 3 | [0001831942] | |
| 4 | [0001831942] | |
| SC 13G | [0001831942] |
| Form 3/4/5 Subject | 2011 - 2024 |
|---|---|
| Vera Therapeutics, Inc. | |
| Commodore Capital LP | |
| Vistagen Therapeutics, Inc. | |
| Ambrx Biopharma Inc. | |
| Enliven Therapeutics, Inc. | |
| Satsuma Pharmaceuticals, Inc. |
| Comparable Firms | State | AUM ($BB) |
|---|---|---|
|
Nipun Capital LP
✚
|
CA | 1.4 |
|
Ajovista LLC
✚
|
MA | 1.4 |
|
EAM Global Investors LLC
✚
|
CA | 1.4 |
|
Duality Advisers LP
✚
|
FL | 1.4 |
|
Alta Fundamental Advisers LLC
✚
|
NY | 1.4 |
|
Seven Eight Capital LP
✚
|
NY | 1.3 |
|
Concentric Capital Strategies LP
✚
|
CT | 1.3 |
|
Governors Lane LP
✚
|
NY | 1.3 |
|
Dendur Capital LP
✚
|
NY | 1.3 |
|
Ashe Capital Management LP
✚
|
NJ | 1.3 |